CAJ | 학술논문

目的：比较利培酮联合舒血宁与利培酮联合安慰剂治疗慢性精神分裂症的疗效和安全性。方法慢性精神分裂症患者82例，随机分为利培酮联合舒血宁治疗组（研究组）和利培酮联合安慰剂治疗组（对照组），各41例。使用阳性与阴性症状评定量表（PANSS）和精神药物副反应量表（TESS）评定临床疗效和不良反应。治疗前和治疗第4、8、12周末评估PANSS，治疗前和治疗12周末评估TESS。结果研究组有效率46.34%，对照组为21.95%，两组比较差异有统计学意义（P<0.05）。研究组低血压、心动过速发生率高于对照组，迟发性运动障碍和心电图异常发生率低于对照组（P<0.05）。结论利培酮联合舒血宁治疗慢性精神分裂症疗效优于单用利培酮，不良反应少。
목적：비교리배동연합서혈저여리배동연합안위제치료만성정신분렬증적료효화안전성。방법만성정신분렬증환자82례，수궤분위리배동연합서혈저치료조（연구조）화리배동연합안위제치료조（대조조），각41례。사용양성여음성증상평정량표（PANSS）화정신약물부반응량표（TESS）평정림상료효화불량반응。치료전화치료제4、8、12주말평고PANSS，치료전화치료12주말평고TESS。결과연구조유효솔46.34%，대조조위21.95%，량조비교차이유통계학의의（P<0.05）。연구조저혈압、심동과속발생솔고우대조조，지발성운동장애화심전도이상발생솔저우대조조（P<0.05）。결론리배동연합서혈저치료만성정신분렬증료효우우단용리배동，불량반응소。
Objective To compare the efficacy and safety of risperidone combined with Shuxuening versus risperidone combined with placebo in the treatment of patients with chronic schizophrenia. Methods Eighty-two patients admitted in Tongde Hospital were randomly divided into risperidone combined with Shuxuening group (study group, n=41) or risperidone combined with placebo group(control group, n=41). Drugs were given for 12 weeks. Positive and Negative Syndrome Scale(PANSS) and Treatment Emergent Symptom Scale(TESS) were as-sessed in two groups before treatment and at the 4th, 8th and 12th week during treatment. Results The effective rate was 46.34% and 21.95% in study group and control group, respectively, with a significant difference between them(P<0.05). Compared with control group, the incidence of tachycardia and hypotension was higher and the inci-dence of tardive dyskinesia and abnormal electrocardiographic pattern was lower in study group(all P<0.05). Con-clusion Risperidone combined with Shuxuening is more effective in treatment of chronic schizophrenia than risperidone combined with placebo does, with less adverse events.